Transformative advancements in immune checkpoint inhibitor therapy for Oropharyngeal Squamous Cell Carcinoma (OPSCC)

Advancements in Immune checkpoint inhibitor (ICI) treatment have greatly changed the way oropharyngeal squamous cell carcinoma (OPSCC) is treated. This paper examines the crucial advancements and their consequences for clinical practice. Initially, the implementation of ICIs, such as pembrolizumab a...

Full description

Bibliographic Details

Published in:	Oral Oncology Reports
Main Authors:	Iadalin Ryntathiang, Mukesh Kumar Dharmalingam Jothinathan
Format:	Article
Language:	English
Published:	Elsevier 2024-09-01
Subjects:	Immune checkpoint inhibitor (ICI) Oropharyngeal squamous cell carcinoma (OPSCC) Tumor microenvironment Pembrolizumab Nivolumab
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772906024004102